[Featured Stock] Hwail Pharm Gains on News of Absorption Merger with Kumho HT and Dinona
[Asia Economy Reporter Yoo Hyun-seok] Hwail Pharmaceutical is showing strong performance.
As of 10:41 AM on the 27th, Hwail Pharmaceutical was trading at 12,750 KRW, up 8.51% (1,000 KRW) compared to the previous trading day.
The news of Kumho HT's merger by absorption with Dinona is interpreted as the reason for the strong performance of Hwail Pharmaceutical, an affiliate company.
On this day, Kumho HT announced that it had decided to merge by absorption with Dinona, a developer of immune-oncology antibody therapeutics. The merger ratio between Kumho HT and Dinona is 1 to 1.7390213, and the merger date is July 12.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Union "General Strike Suspended...Tentative Agreement to Be Put to Vote"
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
According to the announcement on the 26th, Hwail Pharmaceutical's largest shareholders have changed to Dinona and two others (Oseong Advanced Materials, S-Mac), holding 24.05% (5,260,266 shares).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
